Share
5,330 Posts.
lightbulb Created with Sketch. 32
clock Created with Sketch.
20/02/15
14:05
Share
Hi Chips,
You could also consider applying this same analogy the next time either yourself or one of the kids need to go to the GP for your next vaccine jab. Ask your doctor why he/she keeps administering it into the muscle when your sweet immune spot is actually just below the skin?
If you're still skeptical about Prof. Frazer collaborating with Vaxxas on the Nanopatch program this may help to alleviate some of your doubt...
If you're still skeptical about the Admedus/Frazer vaccine initiatives using some kind of unique delivery method to ensure a robust immune response this may help to alleviate some of your doubt...
Immunotherapies
Admedus is developing a range of therapeutic vaccines through our investment in the Research & Development of immunotherapies based on Professor Ian Frazer’s next-generation vaccine technology.
Our scientific team is developing a suite of vaccines that treat and prevent infectious diseases and cancers caused by Herpes Simplex Virus and Human Papillomavirus (HPV). Admedus recently announced that the HPV therapeutic vaccine has progressed well in preclinical studies. Our company will now advance the programme into a Phase Ib study. The unique delivery mechanism of our vaccine ensures that there is a stronger and more effective immune response creating both a therapeutic (treat) and prophylactic (prevent) effect. Admedus is focused on commercialising a new era of therapeutic vaccines.
Admedus
Expand
If you're still skeptical about the Admedus HPV vaccine developments having any direct connection to the Nanopatch program this may help to alleviate some of your doubt...
Skin vaccination against cervical cancer associated human papillomavirus with a novel micro-projection array in a mouse model
Corbett HJ 1, Fernando GJ , Chen X , Frazer IH , Kendall MA .
BACKGROUND:
Better delivery systems are needed for routinely used vaccines, to improve vaccine uptake. Many vaccines contain alum or alum based adjuvants. Here we investigate a novel dry-coated densely-packed micro-projection array skin patch (Nanopatch™) as an alternate delivery system to intramuscular injection for delivering an alum adjuvanted human papillomavirus (HPV) vaccine (Gardasil®) commonly used as a prophylactic vaccine against cervical cancer.
METHODOLOGY/PRINCIPAL FINDINGS:
Micro-projection arrays dry-coated with vaccine material (Gardasil®) delivered to C57BL/6 mouse ear skin released vaccine within 5 minutes. To assess vaccine immunogenicity, doses of corresponding to HPV-16 component of the vaccine between 0.43 ± 0.084 ng and 300 ± 120 ng (mean ± SD) were administered to mice at day 0 and day 14. A dose of 55 ± 6.0 ng delivered intracutaneously by micro-projection array was sufficient to produce a maximal virus neutralizing serum antibody response at day 28 post vaccination. Neutralizing antibody titres were sustained out to 16 weeks post vaccination, and, for comparable doses of vaccine, somewhat higher titres were observed with intracutaneous patch delivery than with intramuscular delivery with the needle and syringe at this time point.
CONCLUSIONS/SIGNIFICANCE:
Use of dry micro-projection arrays (Nanopatch™) has the potential to overcome the need for a vaccine cold chain for common vaccines currently delivered by needle and syringe, and to reduce risk of needle-stick injury and vaccine avoidance due to the fear of the needle especially among children.
Skin vaccination against cervical cancer associated human papillomavirus with a novel micro-projection array in a mouse model.
Expand
and this...
and this...
Nanopatch targeted delivery of both antigen and adjuvant to skin synergistically drives enhanced antibody responses
and this...
Improving the reach of vaccines to low-resource regions, with a needle-free vaccine delivery device and long-term thermostabilization.
and this...
Dry-coated microprojection array patches for targeted delivery of immunotherapeutics to the skin.
and this...
Colocalization of cell death with antigen deposition in skin enhances vaccine immunogenicity.
and this...
Microprojection arrays to immunise at mucosal surfaces
Now, we just need to educate the rest of the market
Last edited by
abdm :
20/02/15